The expanding use of immunosuppression in the treatment of non-infectious ocular disease.
Cyclosporin has been used for an increasing number of ocular indications. This review attempts to put into perspective the present scope of cyclosporin use in the treatment of ophthalmic disorders. This includes a review of randomized masked trials performed to date and work done to minimize and characterize cyclosporin induced renal toxicity. In addition, the ocular surface is an ideal target for topical cyclosporin therapy, and the status of this therapeutic approach is reviewed.
Nussenblatt
R
R
Laboratory of Immunology, National Eye Institute, NIH, Bethesda, MD 20892.
D001971:Bromocriptine / Q000627:therapeutic use; D016039:Corneal Transplantation; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007637:Keratoconjunctivitis / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy
D001971:Bromocriptine; D016572:Cyclosporine; D011241:Prednisone